Date: 2011-01-13
Type of information: Fundraising
Company: Complix (Belgium)
Investors: Credit Agricole Private Equity (France)
Amount: €2 million
Funding type: series A financing round
Planned used: This funding will allow Complix to build a preclinical portfolio of Alphabody based products for treatment of autoimmune and viral diseases. It will also be used to develop its lead product up to regulatory filing for initiation of clinical trials in the second half of 2012.
Others: Complix has raised an additional €2 million from Credit Agricole Private Equity as part as an extension of its series A equity financing round, bringing the total amount of this round to €7 million. In June 2010, the company has already completed a €5 million first closing with Vesalius Biocapital and LRM. Complix was created in 2008 with seed capital from Gemma Frisius Fund, Baekeland Fund, Vinnof and Trustcapital. The company is focused on the development of Alphabody™ based therapies for autoimmune diseases (rheumatoid arthritis, psoriasis and multiple sclerosis), and for infectious diseases, in particular viral diseases. Alphabodies™ are small, extremely stable proteins with distinct structural and functional properties, offering significant advantages over existing protein based therapies. They bind with high affinity to a wide range of disease targets and are particularly suited to address certain target types that are difficult to access with antibodies or other protein scaffolds. Their structure is totally unrelated to immunoglobulins. Due to their unique stability and versatility Alphabodies™ have the potential to be formulated for non-injectable routes of administration, such as pulmonary inhalation or oral delivery for intestinal targeting.
Therapeutic area: Autoimmune diseases - Infectious diseases
